Treatment of a compound heterozygous familial hypercholesterolemia patient with lomitapide

Objectives: The aim of this study is to evaluate the effects of Lomitapide, the first MTP-inhibitor recently approved by FDA and EMA for treatment of homozygous and compound heterozygous familial hypercholesterolemia (FH) patients. These patients present with severely increased LDL-cholesterol levels due to absence/dysfunction of LDL-receptors and consequently, with an extremely increased risk of cardiovascular disease (CVD) and early death. Conventional treatments are not sufficient in reducing the risk of CVD.